Back to top
more

Boston Scientific (BSX)

(Real Time Quote from BATS)

$103.86 USD

103.86
156,105

+0.90 (0.87%)

Updated Aug 8, 2025 10:08 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (153 out of 244)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).

Zacks Equity Research

Should You Retain Teleflex Stock in Your Portfolio Right Now?

by Zacks Equity Research

TFX stays on investors' radars due to its performance in the Vascular Access segment and expansion moves.

Urmimala Biswas headshot

Medtronic Stock Declines 5.6% in a Month: Time to Buy the Dip?

by Urmimala Biswas

MDT stock suffers as a result of geopolitical complications and supply issues despite an expanding portfolio and strong strategic executions.

Zacks Equity Research

All You Need to Know About Boston Scientific (BSX) Rating Upgrade to Buy

by Zacks Equity Research

Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how AxoGen (AXGN) and Boston Scientific (BSX) have performed compared to their sector so far this year.

Zacks Equity Research

Should You Retain Henry Schein Stock in Your Portfolio Right Now?

by Zacks Equity Research

Investors are optimistic about HSIC owing to the performance of its dental business.

Urmimala Biswas headshot

BSX Trades Near 52-Week High: Does the Stock Hold More Potential?

by Urmimala Biswas

We believe Boston Scientific is one of those MedTech manufacturers that can be considered as the biggest gainers from the Fed's two successive interest rate cuts in 2024.

Zacks Equity Research

Boston Scientific (BSX) Stock Moves -0.03%: What You Should Know

by Zacks Equity Research

In the latest trading session, Boston Scientific (BSX) closed at $90.43, marking a -0.03% move from the previous day.

Zacks Equity Research

Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now?

by Zacks Equity Research

Strategic progress and solid potential in oncology testing keep MYGN on investors' radar.

Zacks Equity Research

Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Boston Scientific (BSX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Zacks Equity Research

Is it Apt to Hold Edwards Lifesciences Stock in Your Portfolio Now?

by Zacks Equity Research

Edward Lifesciences' robust potential in Structural heart and long-term strategy instill optimism.

Zacks Equity Research

Innovations and Buyouts Support BSX Stock Amid Macroeconomic Woes

by Zacks Equity Research

Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.

Zacks Equity Research

Boston Scientific (BSX) Ascends But Remains Behind Market: Some Facts to Note

by Zacks Equity Research

Boston Scientific (BSX) closed the most recent trading day at $90.56, moving +0.4% from the previous trading session.

Zacks Equity Research

Should You Continue to Hold TMO Stock in Your Portfolio?

by Zacks Equity Research

Investors continue to be optimistic about Thermo Fisher due to its strategic acquisitions and string of product launches.

Zacks Equity Research

Should You Continue to Retain Insulet Stock in Your Portfolio Now?

by Zacks Equity Research

PODD stock stays on investors' radar owing to its solid progress with Omnipod 5 and robust potential in the diabetes market.

Zacks Equity Research

Why Is SurModics (SRDX) Up 4% Since Last Earnings Report?

by Zacks Equity Research

SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Boston Scientific (BSX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

by Zacks Equity Research

Boston Scientific (BSX) closed at $90.53 in the latest trading session, marking a -0.34% move from the prior day.

Zacks Equity Research

Should You Continue to Retain QIAGEN Stock in Your Portfolio Now?

by Zacks Equity Research

QGEN's robust expansion of its testing menu and potential in molecular diagnostics bode well for investors.

Zacks Equity Research

Is Penumbra Stock a Smart Buy for Your Portfolio Right Now?

by Zacks Equity Research

PEN stays on investors' radars due to its robust portfolio expansion and international growth plans.

Zacks Equity Research

Should You Continue to Retain Bio-Techne Stock in Your Portfolio?

by Zacks Equity Research

Bio-Techne's success with four growth verticals and expansion through acquisitions bode well.

Zacks Equity Research

Why Is Zimmer (ZBH) Up 4.8% Since Last Earnings Report?

by Zacks Equity Research

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Is it the Right Time to Hold Charles River Stock in Your Portfolio?

by Zacks Equity Research

Investors are optimistic about CRL stock due to its strong RMS prospects and inorganic growth efforts.

Zacks Equity Research

International Expansion Supports BSX Stock Amid Macroeconomic Woes

by Zacks Equity Research

BSX's Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of gastrointestinal (GI) and pulmonary treatment options.

Zacks Equity Research

Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Boston Scientific (BSX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Zacks Equity Research

BSX Stock Set to Gain From Agreement to Acquire Intera Oncology

by Zacks Equity Research

Boston Scientific's new buyout is set to expand its interventional oncology offerings.

Zacks Equity Research

Why Is Boston Scientific (BSX) Up 7.5% Since Last Earnings Report?

by Zacks Equity Research

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.